New study reveals immune link between Epstein-Barr virus and multiple sclerosis

Scientists have made significant strides in understanding the link between the Epstein-Barr virus (EBV) and multiple sclerosis (MS), a debilitating autoimmune disease. Following a 2022 study that established a correlation between EBV infection and a higher risk of MS, new research offers critical insights into the immune processes involved.

The latest study focuses on the immune response within patients diagnosed with MS. Researchers observed that specific immune cells, known as CD4+ T cells, in individuals with MS exhibited a significantly stronger reaction to components of the EBV. This heightened response was approximately double that seen in healthy individuals, suggesting a direct link between the virus and the disease's underlying biological mechanisms.

These findings are particularly important because while over 95% of adults are infected with EBV, only a small fraction develop MS. The study helps clarify why this disparity exists by identifying potential immune pathways. The research indicates that these T cell responses to the virus were reduced by a therapy targeting B cells (anti-CD20 antibodies), which also decreased viral shedding in saliva.

This work lays the groundwork for the rational design and monitoring of targeted vaccines and antiviral treatments. Pablo Villoslada, head of Neurology at the Hospital del Mar in Barcelona, described the study as excellent, noting that it demonstrates how CD4+ T cells in MS patients become activated in response to the virus. The research provides crucial data that could lead to new preventative strategies and therapies for MS, which remains the primary cause of neurological disability among young adults.